biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Everyone needs to relax!

<< Previous

Bullboard Posts

Next >>

Comment by JDavenporton Dec 14, 2022 5:47pm

151 Views

Post# 35171957

RE:Everyone needs to relax!

Did xB3 fail, zwerp2000? Is that the program failure?

I think this deal is all about extracting xB3 from shareholder hands.

If xB3 works as hoped then this deal is not caused by xB3 failure. Shareholders had every reason to expect success.

This deal is the result of 14 years of management failure. How can Ladenburg Thalmann and the Midatech people have any respect for DrDR when they scooped this up so easily?

jd

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec